Target intelligence / Profile preview

T-cell immunoglobulin and mucin domain-containing protein 4 (TIM-4) (TIM-4)

Target
TIM-4
Molecular classification
Receptor, TIM family, Type I transmembrane protein
01

Overview

T-cell immunoglobulin and mucin domain-containing protein 4 (TIM-4) is a cell surface receptor primarily expressed on professional antigen-presenting cells, including macrophages and dendritic cells (UniProt: Q6U7R4). It serves as a critical receptor for phosphatidylserine, a phospholipid that is translocated to the outer leaflet of the plasma membrane during apoptosis, thereby facilitating the recognition and engulfment of dying cells, a process known as efferocytosis (PubMed: 17850460). While TIM-4 lacks a classical intracellular signaling domain, it plays a significant role in modulating immune responses and maintaining peripheral tolerance. In oncology, TIM-4 is often exploited by the tumor microenvironment; its expression on tumor-associated macrophages can lead to the suppression of anti-tumor T-cell activity (PubMed: 23602551). Experimental therapeutic approaches utilize anti-TIM-4 monoclonal antibodies to block the interaction between TIM-4 and phosphatidylserine, aiming to promote a more pro-inflammatory environment and enhance the efficacy of cancer vaccines and other immunotherapies. Additionally, TIM-4 has been implicated in the pathogenesis of allergic diseases and various autoimmune conditions due to its role in regulating Th2 cell expansion.

Other names
Timd4TIM4SMUCKLERSpleen, mucin-containing, knockout of lymph node receptor
02

Mechanism of action

Antagonism of phosphatidylserine binding to prevent efferocytosis-mediated immunosuppression and enhance T-cell activation.

03

Biological functions

EfferocytosisImmune responsePhagocytosisT-cell regulationPhosphatidylserine binding
04

Disease associations

CancerAutoimmune diseaseAllergyInflammation
05

Safety considerations

Impaired clearance of apoptotic cells leading to secondary necrosisSystemic inflammationPotential for inducing autoimmune-like syndromes
06

Interacting drugs

Anti-TIM-4 monoclonal antibodies (e.g., RMT4-54, 21H12, 5G3)
07

Biomarkers

TIM-4 expression on tumor-associated macrophagesPhosphatidylserine exposure on tumor cells

Beyond the preview

Go deeper on T-cell immunoglobulin and mucin domain-containing protein 4 (TIM-4) (TIM-4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-cell immunoglobulin and mucin domain-containing protein 4 (TIM-4) (TIM-4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call